Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pharmaceutical Tacalyx Raises €14M from Extended Funding
blood cancer (1)

Tacalyx Raises €14M from Extended Funding

12th June 2024

Tacalyx, a biotech company that focuses on cancer, has expanded its initial fundraising phase to raise more than €14 million.

The reasoning behind Tacalyx is that antibodies against TACA can facilitate the targeted killing of cancerous cells and be utilised to create therapeutic agents such as T cell engagers (TCEs) or antibody-drug conjugates (ADCs).

 

The business’s chemical framework has been used to generate its anti-TACA antibodies. In order to facilitate the identification of novel TACAs, Tacalyx has also formed a number of university partnerships to broaden its research pipeline.

 

Tacalyx CEO Dr Peter Sondermann stated: “With these added funds, we will be able to make significant progress on two of our assets to the clinical candidate stage, and advance others so they are ready for preclinical development.”

 

Leading the additional funding investment was Thuja Capital, a recent Tacalyx backer. Evan Castiglia, a partner at Thuja Capital, will serve on Tacalyx’s board of directors as an aspect of the investment.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.